<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074944</url>
  </required_header>
  <id_info>
    <org_study_id>GZGD03109</org_study_id>
    <secondary_id>2009-015811-42</secondary_id>
    <secondary_id>EFC12818</secondary_id>
    <nct_id>NCT01074944</nct_id>
  </id_info>
  <brief_title>A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)</brief_title>
  <official_title>A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the efficacy and safety of once daily
      (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants
      with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of
      eliglustat tartrate (Genz-112638). The secondary objective was to evaluate the
      pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) was administered
      QD and BID in participants with Gaucher disease type 1 who had demonstrated clinical
      stability on BID dosing of eliglustat tartrate (Genz-112638).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOTE: Other Phase 3 studies being conducted with eliglustat tartrate (Genz-112638) are
      GZGD02507 (ENGAGE): NCT00891202 and GZGD02607 (ENCORE): NCT00943111
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP</measure>
    <time_frame>PAP Baseline up to the end of PAP (Week 52)</time_frame>
    <description>Participants were considered as stable if they met all of the following criteria: 1) no more than 2 bone crisis during PAP (with no more than 1 bone crisis during either the first 6 months or the later 6 months of the period), and were free of other clinically symptomatic bone disease during the entire 52-week PAP; 2) hemoglobin level not decreased &gt;1.5 g/dL from Baseline for PAP; 3) platelet count not decreased &gt;25% from Baseline for PAP; 4) spleen volume (in multiples of normal [MN]) did not increase &gt;25% from Baseline for PAP; 5) liver volume (in MN) did not increase &gt;20% from Baseline for PAP. Baseline for PAP was defined as the last assessment prior to randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26 and 52</measure>
    <time_frame>Baseline, Week 26, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Platelet Count at Baseline, Weeks 26, 52</measure>
    <time_frame>Baseline, Week 26, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Spleen Volume at Baseline, Weeks 26, 52</measure>
    <time_frame>Baseline, Week 26, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Liver Volume at Baseline, Weeks 26, 52</measure>
    <time_frame>Baseline, Week 26 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26 and Week 52</measure>
    <time_frame>Baseline, Week 26, Week 52</time_frame>
    <description>Chitotriosidase biomarker was assayed from plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26 and Week 52</measure>
    <time_frame>Baseline, Week 26 and week 52</time_frame>
    <description>GL-1 on DBS biomarker was assayed from dried blood spot (DBS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Mean Biomarker Macrophage Inflammatory Protein-1 Beta (MIP1-beta) Value at Baseline, Weeks 26, 52</measure>
    <time_frame>Baseline, Week 26, Week 52</time_frame>
    <description>MIP1-beta biomarker was assayed from plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Bone Mineral Density (BMD) at Baseline and Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>BMD measurements of the spine and bilateral femur were acquired by dual-energy x-ray absorptiometry (DXA) scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Total T-Scores for BMD at Baseline and Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. The T-score bone density categories were: normal (score &gt;-1), osteopenia (score -2.5 to &lt;=-1), and osteoporosis (score &lt;= -2.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Total Z-scores for BMD at Baseline and Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score &gt;-2) and below normal (score &lt;=-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Number of Participants With Mobility Status Asessments (MS) at Baseline, Weeks 26, and 52.</measure>
    <time_frame>Baseline, Week 26 and Week 52</time_frame>
    <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Number of Participants With Bone Crises at Baseline, Weeks 26 and 52</measure>
    <time_frame>Baseline, Week 26, and Week 52</time_frame>
    <description>Bone crisis was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crisis, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, and 2= 2 bone crises during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26 and 52</measure>
    <time_frame>Baseline, Week 26, and Week 52</time_frame>
    <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain during the past 4 weeks. In this outcome, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAP: Total Bone Marrow Burden Score (BMB) at Baseline and Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>BMB Score was measured using magnetic resonance imaging (MRI), range from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) -16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week, 52, and Week 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Platelet Count at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Liver Volume at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Spleen Volume at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26, 52, and 78</measure>
    <time_frame>Baseline, Week 26, Week 52 and Week 78</time_frame>
    <description>Chitotriosidase biomarker was assayed from plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26, Week 52, and Week 78</measure>
    <time_frame>Baseline, Week 26, Week 52 and Week 78</time_frame>
    <description>GL-1 on DBS biomarker was assayed from dried blood spot.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Mean Biomarker (MIP1-beta) Value at Baseline, Week 78</measure>
    <time_frame>Baseline and Week 78</time_frame>
    <description>MIP1-beta biomarker was assayed from plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Number of Participants With Mobility Status (MS) at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
    <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Number of Participants With Bone Crises Assessment at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
    <description>Bone crises was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crises, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, 2= 2 bone crises, 6= 6 bone crises, and 24= 24 bone crises during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LIP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26, 52 and 78</measure>
    <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
    <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain. In this outcome, number of participants with different type of bone pain during the past 4 weeks at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Percentage of Participants Who Maintained a Stable Bone Criterion ,Hemoglobin Level, Platelet Count, Liver Volume and Spleen Volume at 1 Year and 2 Years</measure>
    <time_frame>1 Year, 2 Years</time_frame>
    <description>Participant were considered as stable if they met the following criteria: hemoglobin level did not decrease &gt;1.5 g/dL from baseline for PAP, platelet count does not decrease &gt;25% below Baseline for PAP, liver volume does not increase &gt;20% above Baseline for PAP, spleen volume does not increase &gt;25% above Baseline for PAP. Baseline for PAP was defined as last available assessment prior to randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Number of Participants With Mobility Status (MS) at Baseline, 1 Year and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Number of Participants With Bone Crises Assessment at Baseline, 1 Year and 2 Years</measure>
    <time_frame>Baseline, 1 year and 2 years</time_frame>
    <description>Bone crises was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crises, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crises, 1= 1 bone crisis during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year and 2 years</time_frame>
    <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain. In this outcome, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Bone Mineral Density (BMD) at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>BMD measurements of the spine and bilateral femur were acquired by DXA scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Total T-Scores for BMD at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. The T-score bone density categories were: normal (score &gt;-1), osteopenia (score -2.5 to &lt;=-1), and osteoporosis (score &lt;= -2.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Total Z-scores for BMD at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score &gt;-2) and below normal (score &lt;=-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Total Bone Marrow Burden Score (BMB) at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>BMB Score was measured using MRI, range from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) -16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Mean Biomarker (Chitotriosidase) Value at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>Chitotriosidase biomarker was assayed from plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Mean Biomarker (GL-1 on DBS) Value at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>GL-1 on DBS biomarker was assayed from dried blood spot.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTTP: Mean Biomarker (MIP1-beta) Value at Baseline, 1 Year, and 2 Years</measure>
    <time_frame>Baseline, 1 year, and 2 years</time_frame>
    <description>MIP1-beta biomarker was assayed from plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Twice Daily (BID) Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive either 50 mg BID or 100 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Once Daily (QD) Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive either 100 mg QD or 200 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eliglustat tartrate</intervention_name>
    <description>Oral Capsule in 50 mg or 100 mg dosages</description>
    <arm_group_label>Twice Daily (BID) Dose Regimen</arm_group_label>
    <arm_group_label>Once Daily (QD) Dose Regimen</arm_group_label>
    <other_name>Genz-112638</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participant who was willing and provided signed informed consent prior to any
             study-related procedures.

          -  The participant was ≥18 years of age.

          -  The participant diagnosed with GD 1 confirmed by a documented deficiency of acid
             β-glucosidase activity by enzyme assay.

          -  Female participants of childbearing potential had a documented negative pregnancy test
             prior to administration of the first dose of eliglustat tartrate (Genz-112638) in this
             study. In addition, all female participants of childbearing potential used a medically
             accepted form of contraception throughout the study, i.e., either a barrier method or
             hormonal contraceptive with norethindrone and ethinyl estradiol or similar active
             components

          -  The participant met all of the following criteria at the time of screening: hemoglobin
             level ≥9 g/dL (mean of 2 measurements); platelet count ≥70,000/mm^3 (mean of 2
             measurements); spleen volume ≤25 multiples of normal (MN); liver volume ≤2.0 MN.

          -  The participant consented to provide a blood sample for genotyping for Gaucher disease
             and for CYP2D6 to categorize the participant's predicted rate of metabolism, if these
             genotyping results were not already available for the participant.

          -  The participant was willing to abstain from consumption of grapefruit, grapefruit
             juice, or grapefruit products for 72 hours prior to administration of the first dose
             of Genz-112638 and throughout the duration of the study.

        Exclusion Criteria:

          -  The participant was participating in GZGD02607 study, &quot;A Phase 3, Randomized,
             Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the
             Efficacy and Safety of Genz-112638 in Participants with GD1 who have been Stabilized
             with Cerezyme ® ,&quot; or was eligible for inclusion in GZGD02607 (while enrollment was
             ongoing) and had access to a physician participating in GZGD02607, or the participant
             was participating in GZGD02507 study, &quot;A Phase 3, Randomized, Double-Blind,
             Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of
             Genz-112638 in Participants with GD1,&quot; or was eligible for inclusion in GZGD02507
             (while enrollment was ongoing) and had access to a physician participating in
             GZGD02507.

          -  The participant received miglustat within 6 months prior to administration of the
             first dose of Genz-112638 in this study.

          -  The participant had a partial or total splenectomy within 3 years prior to
             randomization.

          -  The participant received pharmacological chaperones or miglustat within 6 months prior
             to administration of the first dose of eliglustat tartrate (Genz-112638) in this
             study.

          -  The participant had any evidence of neurologic disorder (e.g., peripheral neuropathy,
             tremor, seizures, Parkinsonism or cognitive impairment) or pulmonary involvement
             (e.g., pulmonary hypertension) as related to Gaucher disease.

          -  The participant was transfusion-dependent.

          -  The participant had a documented deficiency of iron, vitamin B-12, or folate that
             requires treatment not yet initiated or, if initiated, the participant had not been
             stable under treatment for at least 3 months prior to administration of the first dose
             of Genz-112638 in this study.

          -  The participant had documented prior esophageal varices or clinically significant
             liver infarction or current liver enzymes (alanine transaminase [ALT]/aspartate
             aminotransferase [AST]) or total bilirubin &gt;2 times the upper limit of normal (ULN),
             unless the participant had a diagnosis of Gilbert Syndrome.

          -  The participant had any clinically significant disease, other than Gaucher disease,
             including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic,
             endocrine, metabolic (including hypokalaemia or hypomagnesemia), or psychiatric
             disease, other medical conditions, or serious intercurrent illnesses that, in the
             opinion of the Investigator, precluded participation in the study.

          -  The participant was known to have any of the following: Clinically significant
             coronary artery disease including history of myocardial infarction [MI] or ongoing
             signs or symptoms consistent with cardiac ischemia or heart failure; or clinically
             significant arrhythmias or conduction defect such as 2nd or 3rd degree AV block,
             complete bundle branch block, prolonged QTc interval, or sustained ventricular
             tachycardia (VT).

          -  The participant who tested positive for the human immunodeficiency virus (HIV)
             antibody, Hepatitis C antibody, or Hepatitis B surface antigen.

          -  The participant received an investigational product (other than eliglustat tartrate
             (Genz-112638)) within 30 days prior to administration of the first dose of eliglustat
             tartrate (Genz-112638) in this study.

          -  The participant was scheduled for in-participant hospitalization, including elective
             surgery, during the study.

          -  The participant had a history of cancer, with the exception of basal cell carcinoma,
             within 5 years prior to administration of the first dose of Genz-112638 in this study.

          -  The participant was pregnant or lactating.

          -  The participant had received any medication that may cause QTc interval prolongation
             within 30 days prior to the first dose of Genz-112638. Exception: Diphenhydramine
             (Benadryl) or other medications used as premedication for ERT infusions were allowed
             up to 7 days prior to the first dose of Genz-112638.

          -  The participant had received for the first time (i.e., the participant was not already
             chronically using) any of the following medications within 30 days prior to the first
             dose of Genz-112638:

               -  Strong inhibitors of CYP2D6 or CYP3A4;

               -  Inducers of CYP3A4. Exception: Premedications for ERT infusions were allowed up
                  to 7 days prior to the first dose of Genz-112638.

          -  The participant was a CYP2D6 non-poor metabolizer or an indeterminate metabolizer with
             one allele identified as active who was chronically receiving both a strong
             competitive inhibitor of CYP2D6 and a strong competitive inhibitor of CYP3A4 and for
             whom no reasonable alternative medication exists. or

          -  The participant was a CYP2D6 poor metabolizer or an indeterminate metabolizer with
             neither allele known to be active who was chronically receiving a strong competitive
             inhibitor of CYP3A4 and for whom no reasonable alternative medication exists.

        Exception for both cases: Premedications for ERT infusions were allowed up to 7 days prior
        to the first dose of Genz-112638.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O and O Alpan LLC</name>
      <address>
        <city>Springfield</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton, VIC</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth, WA</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cettro - Centro de Tratamento de Oncologia e Hematologia</name>
      <address>
        <city>Brasília</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemocentro - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Tropical de Medicina Reprodutiva e Menopausa - INTRO</name>
      <address>
        <city>Cuiaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Walter Cantidio - HUWC</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemocentro de Ribeirão Preto Núcleo de Hemoterapia de Franca</name>
      <address>
        <city>Franca</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemorio</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas da Universidade Federal do Parana</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IGEIM - Institute of Genetic and Inborn Erros of Metabolism</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Hematonosis Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant Centre de référence des maladies Héréditaires du métabolisme</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;G. Gennimatas&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward Memorial (KEM) Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie Chuou Medical Center</name>
      <address>
        <city>Tsu, Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Divíno Espírito Santo</name>
      <address>
        <city>Ponta Delgada - São Miguel - Açores</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitaulu Clinic de Urgenta</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical and Prophylactic Healthcare Institution; Chelyabinsk Regional Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Research Center of Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Medical Pavlov University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Greece</country>
    <country>India</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00891202?term=genz+ENGAGE&amp;rank=1</url>
    <description>GZGD02507 (NCT00891202) eliglustat tartrate (Genz-112638) Phase 3 Clinical Study in untreated patients with Gaucher disease type 1</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00943111?term=genz+encore&amp;rank=1</url>
    <description>GZGD02607 (NCT00943111) eliglustat tartrate (Genz-112638) Phase 3 Clinical Study in patients with Gaucher disease type 1 who have been stabilized on Cerezyme</description>
  </link>
  <link>
    <url>http://bloodjournal.hematologylibrary.org/cgi/content/full/116/6/893</url>
    <description>A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1</description>
  </link>
  <reference>
    <citation>McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007 Jul;91(3):259-67. Epub 2007 May 16.</citation>
    <PMID>17509920</PMID>
  </reference>
  <reference>
    <citation>Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010 Aug 12;116(6):893-9. doi: 10.1182/blood-2010-03-273151. Epub 2010 May 3.</citation>
    <PMID>20439622</PMID>
  </reference>
  <reference>
    <citation>Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010 Nov 18;116(20):4095-8. doi: 10.1182/blood-2010-06-293902. Epub 2010 Aug 16. Erratum in: Blood. 2011 May 19;117(20):5551.</citation>
    <PMID>20713962</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>October 7, 2016</results_first_submitted>
  <results_first_submitted_qc>October 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2016</results_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher disease</keyword>
  <keyword>Genz-112638</keyword>
  <keyword>beta-glucosidase</keyword>
  <keyword>acid β-glucosidase</keyword>
  <keyword>glucocerebrosidase</keyword>
  <keyword>glucosylceramide</keyword>
  <keyword>D-glucosyl-N-acylsphingosine glucohydrolase</keyword>
  <keyword>substrate reduction therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eliglustat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 45 centers in 17 countries between 1 June 2010 and 6 October 2015. A total of 219 participants were screened, out of which 170 entered into the lead in period (LIP). Remaining 48 participants were screen failures and 1 participant withdrew before entering into the LIP.</recruitment_details>
      <pre_assignment_details>Participant flow divided into 4 periods: LIP:to assess randomization criteria. Primary analysis period (PAP):to assess therapeutic efficacy at 2 dosing regimen in randomized participants. Long-term treatment period (LTTP): to assess long term efficacy. Extended treatment period (ETP):those who were non-randomized after LIP continued in this period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LIP, Eliglustat</title>
          <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual pharmacokinetics (PK) data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
        </group>
        <group group_id="P2">
          <title>PAP, Eliglustat: Once Daily</title>
          <description>All participants who were randomized after meeting all randomization criteria (defined as: no more than 1 bone crisis and was free of other clinically symptomatic bone disease [such as bone pain attributable to osteonecrosis and/or pathological fractures) during the first 6 months of the LIP; mean hemoglobin level of ≥11 g/dL [if female] and ≥12 g/dL [if male]; mean platelet count ≥100,000/mm^3; spleen volume ≤10 times of normal; liver volume ≤1.5 times of normal; had a dose of 50 mg BID or 100 mg BID of eliglustat for at least 4 months and a peak (2-hour) Genz-99067 plasma concentration of &lt;50 ng/mL) after either 26, 52 or 78 weeks of LIP received eliglustat capsules at the total daily dose (TDD) of 100 mg or 200 mg (the TDD they were on before randomization) once daily (QD) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
        </group>
        <group group_id="P3">
          <title>PAP, Eliglustat: Twice Daily</title>
          <description>All participants who were randomized after meeting all randomization criteria (defined as: no more than 1 bone crisis and was free of other clinically symptomatic bone disease [such as bone pain attributable to osteonecrosis and/or pathological fractures) during the first 6 months of the LIP; mean hemoglobin level of ≥11 g/dL [if female] and ≥12 g/dL [if male]; mean platelet count ≥100,000/mm^3; spleen volume ≤10 times of normal; liver volume ≤1.5 times of normal; had a dose of 50 mg BID or 100 mg BID of eliglustat for at least 4 months and a peak (2-hour) Genz-99067 plasma concentration of &lt;50 ng/mL) after either 26, 52 or 78 weeks of LIP, received eliglustat at the TDD 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
        </group>
        <group group_id="P4">
          <title>LTTP, Eliglustat</title>
          <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
        </group>
        <group group_id="P5">
          <title>ETP, Eliglustat</title>
          <description>All participants who did not meet all the randomization criteria at Week 78 of the LIP continued in the ETP and received eliglustat capsules at the same dose as they were receiving at the end of LIP till the end of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Lead-in Period (up to 78 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170">LIP conducted to assess randomization criteria of all participants in single reporting arm.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Primary Analysis Period (up to 52 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="65">Participants who were randomized after LIP received treatment in PAP.</participants>
                <participants group_id="P3" count="66">Participants who were randomized after LIP received treatment in PAP.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliant to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long Term Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="121">Participants who completed PAP (114) including those who considered as treatment failure in PAP (7).</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="95"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transitioned to Commercial Eliglustat</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entered in Period, But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Treatment (up to 42 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25">Participants who were failed to meet the randomization criteria during the lead-in period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transitioned to Commercial Eliglustat</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated (AT) analysis set included all participants who received at least 1 dose of eliglustat during LIP.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who received treatment in LIP (eliglustat 50 mg BID on Day 1 titrated up to 100 mg BID [50 or 100 mg capsules] based on their individual PK data for up to 78 weeks [except for the participants in Japan]. Participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID [50 or 100 mg capsules] based on their individual PK data for up to 78 weeks) and assessed for randomization.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP</title>
        <description>Participants were considered as stable if they met all of the following criteria: 1) no more than 2 bone crisis during PAP (with no more than 1 bone crisis during either the first 6 months or the later 6 months of the period), and were free of other clinically symptomatic bone disease during the entire 52-week PAP; 2) hemoglobin level not decreased &gt;1.5 g/dL from Baseline for PAP; 3) platelet count not decreased &gt;25% from Baseline for PAP; 4) spleen volume (in multiples of normal [MN]) did not increase &gt;25% from Baseline for PAP; 5) liver volume (in MN) did not increase &gt;20% from Baseline for PAP. Baseline for PAP was defined as the last assessment prior to randomization.</description>
        <time_frame>PAP Baseline up to the end of PAP (Week 52)</time_frame>
        <population>Analysis was performed on per protocol (PP) population which included all participants who were at least 80% compliant with investigational medicinal product (IMP) dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP</title>
          <description>Participants were considered as stable if they met all of the following criteria: 1) no more than 2 bone crisis during PAP (with no more than 1 bone crisis during either the first 6 months or the later 6 months of the period), and were free of other clinically symptomatic bone disease during the entire 52-week PAP; 2) hemoglobin level not decreased &gt;1.5 g/dL from Baseline for PAP; 3) platelet count not decreased &gt;25% from Baseline for PAP; 4) spleen volume (in multiples of normal [MN]) did not increase &gt;25% from Baseline for PAP; 5) liver volume (in MN) did not increase &gt;20% from Baseline for PAP. Baseline for PAP was defined as the last assessment prior to randomization.</description>
          <population>Analysis was performed on per protocol (PP) population which included all participants who were at least 80% compliant with investigational medicinal product (IMP) dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="67.6" upper_limit="89.8"/>
                    <measurement group_id="O2" value="83.1" lower_limit="71.0" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Eliglustat QD treatment was declared non-inferior to BID treatment if the lower bound of the 95% confidence interval (CI) for the difference was within the non-inferiority margin of -0.15 (or -15%).</non_inferiority_desc>
            <param_type>Difference in Percentage Stable</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26 and 52</title>
        <time_frame>Baseline, Week 26, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26 and 52</title>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.641" spread="1.214"/>
                    <measurement group_id="O2" value="13.691" spread="1.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.677" spread="1.377"/>
                    <measurement group_id="O2" value="13.946" spread="1.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.605" spread="1.432"/>
                    <measurement group_id="O2" value="13.824" spread="1.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Platelet Count at Baseline, Weeks 26, 52</title>
        <time_frame>Baseline, Week 26, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Platelet Count at Baseline, Weeks 26, 52</title>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
          <units>platelets*10^9 /L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.01" spread="81.49"/>
                    <measurement group_id="O2" value="171.09" spread="63.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=56, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.75" spread="66.65"/>
                    <measurement group_id="O2" value="173.94" spread="65.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.20" spread="80.62"/>
                    <measurement group_id="O2" value="176.10" spread="62.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Spleen Volume at Baseline, Weeks 26, 52</title>
        <time_frame>Baseline, Week 26, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data for specified category for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Spleen Volume at Baseline, Weeks 26, 52</title>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data for specified category for each arm respectively.</population>
          <units>MN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 39, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.309" spread="1.465"/>
                    <measurement group_id="O2" value="3.787" spread="1.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n= 39, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.066" spread="1.299"/>
                    <measurement group_id="O2" value="3.504" spread="1.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 39, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.017" spread="1.381"/>
                    <measurement group_id="O2" value="3.394" spread="1.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Liver Volume at Baseline, Weeks 26, 52</title>
        <time_frame>Baseline, Week 26 and Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Liver Volume at Baseline, Weeks 26, 52</title>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
          <units>MN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" spread="0.187"/>
                    <measurement group_id="O2" value="1.040" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.987" spread="0.190"/>
                    <measurement group_id="O2" value="1.024" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="0.170"/>
                    <measurement group_id="O2" value="1.009" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26 and Week 52</title>
        <description>Chitotriosidase biomarker was assayed from plasma.</description>
        <time_frame>Baseline, Week 26, Week 52</time_frame>
        <population>PP population which all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data for specified category for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26 and Week 52</title>
          <description>Chitotriosidase biomarker was assayed from plasma.</description>
          <population>PP population which all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data for specified category for each arm respectively.</population>
          <units>nmol/hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=55, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1523.7" spread="2556.6"/>
                    <measurement group_id="O2" value="1554.9" spread="1895.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279.6" spread="2328.1"/>
                    <measurement group_id="O2" value="1242.0" spread="2012.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=54, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1076.6" spread="1855.8"/>
                    <measurement group_id="O2" value="1170.1" spread="1683.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26 and Week 52</title>
        <description>GL-1 on DBS biomarker was assayed from dried blood spot (DBS).</description>
        <time_frame>Baseline, Week 26 and week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26 and Week 52</title>
          <description>GL-1 on DBS biomarker was assayed from dried blood spot (DBS).</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GL-1 on DBS: Baseline (n=54, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.257" spread="0.835"/>
                    <measurement group_id="O2" value="2.425" spread="1.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: week 26 (n=54, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.481" spread="1.037"/>
                    <measurement group_id="O2" value="2.563" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: week 52 (n=53, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.853" spread="1.383"/>
                    <measurement group_id="O2" value="2.707" spread="1.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Mean Biomarker Macrophage Inflammatory Protein-1 Beta (MIP1-beta) Value at Baseline, Weeks 26, 52</title>
        <description>MIP1-beta biomarker was assayed from plasma.</description>
        <time_frame>Baseline, Week 26, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data for specified category for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Mean Biomarker Macrophage Inflammatory Protein-1 Beta (MIP1-beta) Value at Baseline, Weeks 26, 52</title>
          <description>MIP1-beta biomarker was assayed from plasma.</description>
          <population>PP population included all participants who were at least 80% compliant with dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data for specified category for each arm respectively.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=54, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" spread="74.4"/>
                    <measurement group_id="O2" value="118.8" spread="156.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=52, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="68.0"/>
                    <measurement group_id="O2" value="121.0" spread="204.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=54, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" spread="82.8"/>
                    <measurement group_id="O2" value="117.9" spread="165.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Bone Mineral Density (BMD) at Baseline and Week 52</title>
        <description>BMD measurements of the spine and bilateral femur were acquired by dual-energy x-ray absorptiometry (DXA) scan.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Bone Mineral Density (BMD) at Baseline and Week 52</title>
          <description>BMD measurements of the spine and bilateral femur were acquired by dual-energy x-ray absorptiometry (DXA) scan.</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine: Baseline (n=51, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.073" spread="0.177"/>
                    <measurement group_id="O2" value="1.081" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine: Week 52 (n=51, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.089" spread="0.183"/>
                    <measurement group_id="O2" value="1.086" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur: Baseline (n=48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" spread="0.219"/>
                    <measurement group_id="O2" value="1.000" spread="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur: Week 52 (n=48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" spread="0.211"/>
                    <measurement group_id="O2" value="0.990" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur: Baseline (n=48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.971" spread="0.217"/>
                    <measurement group_id="O2" value="0.996" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur: Week 52 (n=48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.967" spread="0.213"/>
                    <measurement group_id="O2" value="0.981" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Total T-Scores for BMD at Baseline and Week 52</title>
        <description>Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. The T-score bone density categories were: normal (score &gt;-1), osteopenia (score -2.5 to &lt;=-1), and osteoporosis (score &lt;= -2.5).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Total T-Scores for BMD at Baseline and Week 52</title>
          <description>Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. The T-score bone density categories were: normal (score &gt;-1), osteopenia (score -2.5 to &lt;=-1), and osteoporosis (score &lt;= -2.5).</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine T-Score: Baseline (n=49, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.722" spread="1.415"/>
                    <measurement group_id="O2" value="-0.771" spread="1.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine T-Score: Week 52 (n=49, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.580" spread="1.476"/>
                    <measurement group_id="O2" value="-0.717" spread="1.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur T-Score: Baseline (n=46, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.459" spread="1.385"/>
                    <measurement group_id="O2" value="-0.368" spread="1.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur T-Score: Week 52 (n=46, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.509" spread="1.342"/>
                    <measurement group_id="O2" value="-0.441" spread="1.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur T-score: Baseline (n=46, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.574" spread="1.327"/>
                    <measurement group_id="O2" value="-0.382" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur T-score: Week 52 (n=46, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.607" spread="1.308"/>
                    <measurement group_id="O2" value="-0.530" spread="1.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Total Z-scores for BMD at Baseline and Week 52</title>
        <description>Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score &gt;-2) and below normal (score &lt;=-2).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data for specified category for each arm respectively</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Total Z-scores for BMD at Baseline and Week 52</title>
          <description>Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score &gt;-2) and below normal (score &lt;=-2).</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here 'n' signifies number of participants with available data for specified category for each arm respectively</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine Z-scores: Baseline (n=51, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.492" spread="1.517"/>
                    <measurement group_id="O2" value="-0.609" spread="1.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine Z-scores: Week 52 (n=51, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.324" spread="1.559"/>
                    <measurement group_id="O2" value="-0.555" spread="1.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur Z-scores: Baseline (n= 48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.171" spread="1.316"/>
                    <measurement group_id="O2" value="-0.115" spread="1.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur Z-scores: Week 52 (n= 48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.202" spread="1.250"/>
                    <measurement group_id="O2" value="-0.183" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur Z-scores: Baseline (n= 48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.235" spread="1.251"/>
                    <measurement group_id="O2" value="-0.140" spread="1.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur Z-scores: Week 52 (n= 48, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.248" spread="1.214"/>
                    <measurement group_id="O2" value="-0.260" spread="1.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Number of Participants With Mobility Status Asessments (MS) at Baseline, Weeks 26, and 52.</title>
        <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
        <time_frame>Baseline, Week 26 and Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Number of Participants With Mobility Status Asessments (MS) at Baseline, Weeks 26, and 52.</title>
          <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MS, Unrestricted: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Unrestricted: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Unrestricted: Week 52 (n=51, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Difficulty: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Difficulty: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ms, Walks with Difficulty: Week 52 (n=51, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Orthopedic Aid: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Orthopedic Aid: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Orthopedic Aid: Week 52 (n=51, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required Wheelchair: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required Wheelchair: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required Wheelchair: Week 52 (n=51, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Week 52 (n=51, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Number of Participants With Bone Crises at Baseline, Weeks 26 and 52</title>
        <description>Bone crisis was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crisis, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, and 2= 2 bone crises during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
        <time_frame>Baseline, Week 26, and Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Number of Participants With Bone Crises at Baseline, Weeks 26 and 52</title>
          <description>Bone crisis was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crisis, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, and 2= 2 bone crises during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bone Crisis (0): Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): Week 26 (n=55,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26 and 52</title>
        <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain during the past 4 weeks. In this outcome, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported.</description>
        <time_frame>Baseline, Week 26, and Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26 and 52</title>
          <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain during the past 4 weeks. In this outcome, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported.</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Week 52 (56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Baseline (n=56, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Week 26 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Week 52 (n=56, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAP: Total Bone Marrow Burden Score (BMB) at Baseline and Week 52</title>
        <description>BMB Score was measured using magnetic resonance imaging (MRI), range from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) -16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PAP, Eliglustat: Once Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat at the TDD of 100 mg or 200 mg (the TDD they were on before randomization) QD from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
          <group group_id="O2">
            <title>PAP, Eliglustat: Twice Daily</title>
            <description>All participants who were randomized after either 26, 52 or 78 weeks of LIP received eliglustat 50 mg BID or 100 mg BID (the TDD they were on before randomization) from Day 1 up to Week 52 in PAP (50 or 100 mg capsules).</description>
          </group>
        </group_list>
        <measure>
          <title>PAP: Total Bone Marrow Burden Score (BMB) at Baseline and Week 52</title>
          <description>BMB Score was measured using magnetic resonance imaging (MRI), range from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) -16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement.</description>
          <population>PP population included all participants who were at least 80% compliant with IMP dosing during PAP, had all of the necessary Baseline and Week 52 assessments to evaluate the primary endpoint, and did not have major protocol deviations. Here, 'n' signifies number of participants with available data at specified time points for each arm respectively.</population>
          <units>BMB Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BMB Score: Baseline (n=52, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.276" spread="2.891"/>
                    <measurement group_id="O2" value="9.136" spread="2.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMB Score: Week 52 (n=51, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.971" spread="2.689"/>
                    <measurement group_id="O2" value="8.705" spread="2.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26, 52 and 78</title>
        <time_frame>Baseline, Week 26, Week, 52, and Week 78</time_frame>
        <population>Analysis was performed on all treated (AT) analysis set which included all participants who received at least 1 dose of eliglustat during lead in period. Here 'n' signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg BID on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26, 52 and 78</title>
          <population>Analysis was performed on all treated (AT) analysis set which included all participants who received at least 1 dose of eliglustat during lead in period. Here 'n' signifies number of participants with available data at specified time points.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.435" spread="1.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.443" spread="1.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.434" spread="1.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.329" spread="1.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Platelet Count at Baseline, Weeks 26, 52 and 78</title>
        <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg BID on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Platelet Count at Baseline, Weeks 26, 52 and 78</title>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
          <units>platelets*10^9 /L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.653" spread="92.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.021" spread="85.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.378" spread="79.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.720" spread="74.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Liver Volume at Baseline, Weeks 26, 52 and 78</title>
        <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
        <population>Analysis was performed on AT participants which included all participants who received at least 1 dose of eliglustat during lead in period. Here, 'n' signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg BID on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Liver Volume at Baseline, Weeks 26, 52 and 78</title>
          <population>Analysis was performed on AT participants which included all participants who received at least 1 dose of eliglustat during lead in period. Here, 'n' signifies number of participants with available data at specified time points.</population>
          <units>MN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.044" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.040" spread="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.059" spread="0.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.062" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Spleen Volume at Baseline, Weeks 26, 52 and 78</title>
        <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
        <population>Analysis was performed on AT participants which included all participants who received at least 1 dose of eliglustat during lead in period. Here 'n' signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg BID on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Spleen Volume at Baseline, Weeks 26, 52 and 78</title>
          <population>Analysis was performed on AT participants which included all participants who received at least 1 dose of eliglustat during lead in period. Here 'n' signifies number of participants with available data at specified time points.</population>
          <units>MN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.448" spread="2.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.840" spread="1.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.094" spread="1.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.088" spread="2.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26, 52, and 78</title>
        <description>Chitotriosidase biomarker was assayed from plasma.</description>
        <time_frame>Baseline, Week 26, Week 52 and Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26, 52, and 78</title>
          <description>Chitotriosidase biomarker was assayed from plasma.</description>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
          <units>nmol/hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chitotriosidase: Baseline (n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2437.92" spread="3291.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitotriosidase: week 26 (n=157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1802.93" spread="2529.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitotriosidase: week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1755.70" spread="2649.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitotriosidase: week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1677.02" spread="2718.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26, Week 52, and Week 78</title>
        <description>GL-1 on DBS biomarker was assayed from dried blood spot.</description>
        <time_frame>Baseline, Week 26, Week 52 and Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26, Week 52, and Week 78</title>
          <description>GL-1 on DBS biomarker was assayed from dried blood spot.</description>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GL-1 on DBS: Baseline (n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.358" spread="2.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: Week 26 (n=144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.340" spread="0.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: Week 52 (n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.279" spread="0.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: Week 78 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.495" spread="1.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Mean Biomarker (MIP1-beta) Value at Baseline, Week 78</title>
        <description>MIP1-beta biomarker was assayed from plasma.</description>
        <time_frame>Baseline and Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Mean Biomarker (MIP1-beta) Value at Baseline, Week 78</title>
          <description>MIP1-beta biomarker was assayed from plasma.</description>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP. Here ‘n’ signifies number of participants with available data at specified time points.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIP-1beta: Baseline (n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.433" spread="125.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1beta: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.180" spread="189.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Number of Participants With Mobility Status (MS) at Baseline, Weeks 26, 52 and 78</title>
        <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
        <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Number of Participants With Mobility Status (MS) at Baseline, Weeks 26, 52 and 78</title>
          <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MS,Unrestricted: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS,Unrestricted: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS,Unrestricted: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS,Unrestricted: Week 78 (n= 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Difficulty: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Difficulty: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Difficulty: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Difficulty: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Orthopedic Aid: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Orthopedic Aid: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Orthopedic Aid: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks With Orthopedic Aid: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required wheelchair: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required wheelchair: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required wheelchair: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required wheelchair: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Number of Participants With Bone Crises Assessment at Baseline, Weeks 26, 52 and 78</title>
        <description>Bone crises was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crises, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, 2= 2 bone crises, 6= 6 bone crises, and 24= 24 bone crises during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
        <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Number of Participants With Bone Crises Assessment at Baseline, Weeks 26, 52 and 78</title>
          <description>Bone crises was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crises, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, 2= 2 bone crises, 6= 6 bone crises, and 24= 24 bone crises during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bone Crisis (0): Baseline (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): Week 26 (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Baseline (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Week 26 (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): Baseline (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): Week 26 (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (2): Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (6): Baseline (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (6): Week 26 (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (6): Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (6): Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (24): Baseline (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (24): Week 26 (n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (24): Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (24): Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LIP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26, 52 and 78</title>
        <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain. In this outcome, number of participants with different type of bone pain during the past 4 weeks at specified time points were reported.</description>
        <time_frame>Baseline, Week 26, Week 52, Week 78</time_frame>
        <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP.</population>
        <group_list>
          <group group_id="O1">
            <title>LIP: Eliglustat</title>
            <description>All participants (except in Japan) received eliglustat 50 mg, twice daily (BID) on Day 1 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks. All participants in Japan received eliglustat 50 mg once only on Day 1 and then eliglustat 50 mg BID from Day 2 titrated up to 100 mg BID (50 or 100 mg capsules) based on their individual PK data for up to 78 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>LIP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26, 52 and 78</title>
          <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain. In this outcome, number of participants with different type of bone pain during the past 4 weeks at specified time points were reported.</description>
          <population>Analysis was performed on AT analysis set which included all participants who received at least 1 dose of eliglustat during LIP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Baseline (n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Week 26 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Week 52 (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Week 78 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Percentage of Participants Who Maintained a Stable Bone Criterion ,Hemoglobin Level, Platelet Count, Liver Volume and Spleen Volume at 1 Year and 2 Years</title>
        <description>Participant were considered as stable if they met the following criteria: hemoglobin level did not decrease &gt;1.5 g/dL from baseline for PAP, platelet count does not decrease &gt;25% below Baseline for PAP, liver volume does not increase &gt;20% above Baseline for PAP, spleen volume does not increase &gt;25% above Baseline for PAP. Baseline for PAP was defined as last available assessment prior to randomization.</description>
        <time_frame>1 Year, 2 Years</time_frame>
        <population>Analysis was performed on intent to treat (ITT) population which included all participants who received at least 1 dose of eliglustat after randomization. Here ‘n’ signifies number of participants with available data at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Percentage of Participants Who Maintained a Stable Bone Criterion ,Hemoglobin Level, Platelet Count, Liver Volume and Spleen Volume at 1 Year and 2 Years</title>
          <description>Participant were considered as stable if they met the following criteria: hemoglobin level did not decrease &gt;1.5 g/dL from baseline for PAP, platelet count does not decrease &gt;25% below Baseline for PAP, liver volume does not increase &gt;20% above Baseline for PAP, spleen volume does not increase &gt;25% above Baseline for PAP. Baseline for PAP was defined as last available assessment prior to randomization.</description>
          <population>Analysis was performed on intent to treat (ITT) population which included all participants who received at least 1 dose of eliglustat after randomization. Here ‘n’ signifies number of participants with available data at specified time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bone Criterion Stable at 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="85.4" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Criterion Stable at 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="67.2" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Level Stable at 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="85.4" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Level Stable at 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="63.6" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count Stable at 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="86.6" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count Stable at 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="67.2" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Volume Stable at 1 year (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="86.5" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Volume Stable at 2 years (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="66.3" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen Volume Stable at 1 year (n=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="88.3" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen Volume Stable at 2 years (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Number of Participants With Mobility Status (MS) at Baseline, 1 Year and 2 Years</title>
        <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Number of Participants With Mobility Status (MS) at Baseline, 1 Year and 2 Years</title>
          <description>Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MS, Unrestricted: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Unrestricted: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Unrestricted: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Difficulty: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Difficulty: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ms, Walks with Difficulty: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Orthopedic Aid: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Orthopedic Aid: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Walks with Orthopedic Aid: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required Wheelchair: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required Wheelchair: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Required Wheelchair: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS, Bedridden: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Number of Participants With Bone Crises Assessment at Baseline, 1 Year and 2 Years</title>
        <description>Bone crises was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crises, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crises, 1= 1 bone crisis during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
        <time_frame>Baseline, 1 year and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Number of Participants With Bone Crises Assessment at Baseline, 1 Year and 2 Years</title>
          <description>Bone crises was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crises, which typically causes debilitation lasting several days or longer and requires treatment with immobilization, hydration, and opioid analgesics. Participants were categorized as 0= no bone crises, 1= 1 bone crisis during the assessment period. In this outcome, number of participants with different bone crises levels at specified time points were reported.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bone Crisis (0): Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (0): 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Crisis (1): 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, 1 Year, and 2 Years</title>
        <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain. In this outcome, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported.</description>
        <time_frame>Baseline, 1 year and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, 1 Year, and 2 Years</title>
          <description>Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain. In this outcome, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Mild: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: Baseline (n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: 1 year (n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extreme: 2 years (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Bone Mineral Density (BMD) at Baseline, 1 Year, and 2 Years</title>
        <description>BMD measurements of the spine and bilateral femur were acquired by DXA scan.</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Bone Mineral Density (BMD) at Baseline, 1 Year, and 2 Years</title>
          <description>BMD measurements of the spine and bilateral femur were acquired by DXA scan.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine: Baseline (n=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.087" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine: 1 year (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.083" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine: 2 years (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.082" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur: Baseline (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.986" spread="0.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur: 1 year (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.994" spread="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur: 2 years (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.950" spread="0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur: Baseline (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur: 1 year (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur: 2 years (n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.908" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Total T-Scores for BMD at Baseline, 1 Year, and 2 Years</title>
        <description>Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. The T-score bone density categories were: normal (score &gt;-1), osteopenia (score -2.5 to &lt;=-1), and osteoporosis (score &lt;= -2.5).</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Total T-Scores for BMD at Baseline, 1 Year, and 2 Years</title>
          <description>Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. The T-score bone density categories were: normal (score &gt;-1), osteopenia (score -2.5 to &lt;=-1), and osteoporosis (score &lt;= -2.5).</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine T-Score: Baseline (n=110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.674" spread="1.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine T-Score: 1 year (n=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.718" spread="1.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine T-Score: 2 years (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.750" spread="1.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur T-Score: Baseline (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.421" spread="1.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur T-Score: 1 year (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.382" spread="1.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur T-Score: 2 years (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.682" spread="1.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur T-Score: Baseline (n=99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.461" spread="1.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur T-Score: 1 year (n=87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.500" spread="1.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur T-Score: 2 years (n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.005" spread="0.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Total Z-scores for BMD at Baseline, 1 Year, and 2 Years</title>
        <description>Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score &gt;-2) and below normal (score &lt;=-2).</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Total Z-scores for BMD at Baseline, 1 Year, and 2 Years</title>
          <description>Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score &gt;-2) and below normal (score &lt;=-2).</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine Z-Score: Baseline (n=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.460" spread="1.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine Z-Score: 1 year (n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.512" spread="1.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine Z-Score: 2 years (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.385" spread="1.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur Z-Score: Baseline (n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.164" spread="1.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur Z-Score: 1 year (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.132" spread="1.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Femur Z-Score: 2 years (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.264" spread="1.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur Z-Score: Baseline (n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.214" spread="1.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur Z-Score: 1 year (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.262" spread="1.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Femur Z-Score: 2 years (n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.605" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Total Bone Marrow Burden Score (BMB) at Baseline, 1 Year, and 2 Years</title>
        <description>BMB Score was measured using MRI, range from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) -16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement.</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Total Bone Marrow Burden Score (BMB) at Baseline, 1 Year, and 2 Years</title>
          <description>BMB Score was measured using MRI, range from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) -16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>BMB Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BMB Score: Baseline (n=115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.164" spread="2.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMB Score: 1 year (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.853" spread="2.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMB Score: 2 years (n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.059" spread="1.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Mean Biomarker (Chitotriosidase) Value at Baseline, 1 Year, and 2 Years</title>
        <description>Chitotriosidase biomarker was assayed from plasma.</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Mean Biomarker (Chitotriosidase) Value at Baseline, 1 Year, and 2 Years</title>
          <description>Chitotriosidase biomarker was assayed from plasma.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>nmol/hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chitotriosidase: Baseline (n=118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1188.983" spread="1857.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitotriosidase: 1 year (n=97))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1221.753" spread="2072.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitotriosidase: 2 years (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="598.161" spread="1463.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Mean Biomarker (GL-1 on DBS) Value at Baseline, 1 Year, and 2 Years</title>
        <description>GL-1 on DBS biomarker was assayed from dried blood spot.</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Mean Biomarker (GL-1 on DBS) Value at Baseline, 1 Year, and 2 Years</title>
          <description>GL-1 on DBS biomarker was assayed from dried blood spot.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GL-1 on DBS: Baseline (n=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.725" spread="1.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: 1 year (n=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.500" spread="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GL-1 on DBS: 2 years (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.238" spread="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTTP: Mean Biomarker (MIP1-beta) Value at Baseline, 1 Year, and 2 Years</title>
        <description>MIP1-beta biomarker was assayed from plasma.</description>
        <time_frame>Baseline, 1 year, and 2 years</time_frame>
        <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
        <group_list>
          <group group_id="O1">
            <title>LTTP: Eliglustat</title>
            <description>All participants who entered PAP continued their blinded randomized treatment for first 4 weeks. Participants who at Week 52 of PAP maintained their therapeutic goals (defined as: no more than 2 bone crisis during PAP [with no more than 1 bone crisis during either first 6 months or later 6 months of PAP] and is free of other clinically symptomatic bone disease during PAP; hemoglobin level not decreased by &gt;1.5 g/dL from Baseline for PAP [defined as last available assessment prior to randomization]; platelet count not decreased by &gt;25% from Baseline for PAP; spleen volume not increased by 25% from Baseline for PAP; liver volume not increased by &gt;20% from Baseline for PAP), continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) QD till the end of the study. The participants who did not maintain all their therapeutic goals continued into the LTTP and received their TDD of eliglustat (100 mg or 200 mg) BID till the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>LTTP: Mean Biomarker (MIP1-beta) Value at Baseline, 1 Year, and 2 Years</title>
          <description>MIP1-beta biomarker was assayed from plasma.</description>
          <population>All participants who received at least one dose of eliglustat during the LTTP.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIP-1beta: Baseline (n=114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.857" spread="125.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1beta: 1 year (n=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.398" spread="90.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1beta: 2 years (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.445" spread="64.774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events data was planned to be reported for overall population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Eliglustat</title>
          <description>All participants who received eliglustat at the TDD of 100 mg or 200 mg in the LIP, PAP, LTTP or ETP.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact­US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

